Yet again, a jury sent AbbVie, maker of the popular prescription testosterone drug Androgel, a loud and clear message. A federal jury in Chicago found that AbbVie misrepresented the dangers of using Androgel. And to make sure the drugmaker got their message, it also reached a verdict in excess of $140 million.
This most recent trial is the second bellwether case to be tried in the federal testosterone replacement ...
continue reading...